NCT06294262View on ClinicalTrials.gov

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

March 31, 2025

Conditions
Vaccination Reaction
Interventions
BIOLOGICAL

TETRALITE

Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant

Trial Locations (1)

9000

University Hospital Gent, Ghent

Sponsors

Lead Sponsor

LiteVax BV
All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

collaborator

HarmonyCR, Melle, Belgium

UNKNOWN

lead

LiteVax BV

INDUSTRY